Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study

OBJECTIVE: To address a novel lower-dose rituximab (RTX) therapy strategy based on our clinical experience and assess its efficacy and safety in neuromyelitis optica spectrum disorder (NMOSD). METHODS: A multicenter, open-label, self-controlled, prospective follow-up study. Totally, 108 NMOSD patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Daidi, Ren, Kaixi, Lu, Jiarui, Liu, Zhiqin, Li, Zunbo, Wu, Jun, Xu, Zhihao, Wu, Songdi, Lei, Tao, Ma, Chao, Zhao, Sijia, Bai, Miao, Li, Hongzeng, Guo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442836/
https://www.ncbi.nlm.nih.gov/pubmed/37614240
http://dx.doi.org/10.3389/fimmu.2023.1148632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442836/
https://www.ncbi.nlm.nih.gov/pubmed/37614240
http://dx.doi.org/10.3389/fimmu.2023.1148632

Ejemplares similares